Publications by authors named "Julia Sheehan-Klenk"
Glypican-3 (GPC3) is overexpressed in hepatocellular carcinomas and hepatoblastomas and represents an important therapeutic target but the biologic importance of GPC3 in liver cancer is unclear. To date, there are limited data characterizing the biological implications of GPC3 knockout (KO) in liver cancers that intrinsically express this target. Here, we report on the development and characterization of GPC3-KO liver cancer cell lines and compare to them to parental lines.
View Article and Find Full Text PDFArticle Synopsis
- Radiopharmaceutical therapies (RPT) trigger a type I interferon (IFN1) response in tumor cells, with the response varying based on the type of isotope used.
- In experiments with murine tumor models, the timing and intensity of the IFN1 response were linked to the isotope's half-life and energy transfer properties.
- Combining Ac-NM600 with immune checkpoint inhibitors enhanced survival in wild-type tumors, suggesting that the effectiveness of RPT is influenced by the radioisotope and relies on STING pathways for immune response enhancement.